Inhibition of DDR1‐BCR signalling by nilotinib as a new therapeutic strategy for metastatic colorectal cancer

The clinical management of metastatic colorectal cancer (mCRC) faces major challenges. Here, we show that nilotinib, a clinically approved drug for chronic myeloid leukaemia, strongly inhibits human CRC cell invasion in vitro and reduces their metastatic potential in intrasplenic tumour mouse models...

Full description

Saved in:

Bibliographic Details
Published in:	EMBO molecular medicine Vol. 10; no. 4; pp. 1 - n/a
Main Authors:	Jeitany, Maya, Leroy, Cédric, Tosti, Priscillia, Lafitte, Marie, Le Guet, Jordy, Simon, Valérie, Bonenfant, Debora, Robert, Bruno, Grillet, Fanny, Mollevi, Caroline, El Messaoudi, Safia, Otandault, Amaëlle, Canterel‐Thouennon, Lucile, Busson, Muriel, Thierry, Alain R, Martineau, Pierre, Pannequin, Julie, Roche, Serge, Sirvent, Audrey
Format:	Journal Article
Language:	English
Published:	London Nature Publishing Group UK 01.04.2018 Wiley Open Access John Wiley and Sons Inc Springer Nature
Subjects:	Animals Cellular Biology collagen receptor colorectal cancer Colorectal Neoplasms - metabolism Colorectal Neoplasms - pathology Discoidin Domain Receptor 1 - genetics Discoidin Domain Receptor 1 - metabolism EMBO03 EMBO12 EMBO28 HCT116 Cells HEK293 Cells Humans invasion Life Sciences Mice Phosphoproteins - metabolism Protein-Tyrosine Kinases - genetics Protein-Tyrosine Kinases - metabolism Proto-Oncogene Proteins c-bcr - genetics Proto-Oncogene Proteins c-bcr - metabolism Pyrimidines - pharmacology Receptors, Collagen - genetics Receptors, Collagen - metabolism Research Article Signal Transduction - drug effects Signal Transduction - genetics targeted therapy tyrosine kinase targeted therapy colorectal cancer invasion collagen receptor tyrosine kinase Digestive System Pharmacology & Drug Discovery tyrosine kinase Subject Categories Cancer
ISSN:	1757-4676, 1757-4684, 1757-4684
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!